REGENERA

REGENERA is a Swiss-Austrian biotech and university spin-off aiming at translating into clinics its proprietary innovative combined approach for acute spinal cord injury repair.

Spinal cord injuries, mostly of traumatic origin, are complex multi-factorial pathologies that currently impact circa 250’000 new patients yearly worldwide, leaving most of them with permanent neurological impairments.

Spinal cord injury has still unmet clinical needs: present tentative therapies indeed target at best only single components of this multi-factorial complex pathology.

In this complex framework, REGENERA proposes SpinoSave®, its proprietary innovative combined biomaterial and stem cells paradigm to counteract the cascade of events that follow after cord lesion, to be applied after standard anti-inflammatory therapy during post traumatic stabilization surgery. Trophic support to tissue plasticity will be provided by locally grafting, outside lesioned parenchyma, autologous stem cells duly hosted into its proprietary innovative injectable resorbable hydrogel.

Using the paracrine effect of the stem cells, the damaged tissue will be progressively led toward (self) regeneration to achieve cord functionality restoration.

Classified by EMA as TEP and granted Orphan Drug Designation, SpinoSave® builds on 15+ years of translational research in neuroregeneration, biomaterials and tissue engineering.

Together with neurosurgeons, neuroscientists, SCI units and patient organizations, we work to make paralysis a thing of the past.